Results 191 to 200 of about 165,540 (296)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Impact of oncogenic viruses on autoimmune diseases and tumorigenesis. [PDF]

Infect Agent Cancer
Hamidi Sofiani V, Khodadadpour Mahani F, Farsiu N, Yousefi M, Naderi M, Ahmadi G, Nakhaie M.   +6 more
europepmc   +1 more source

S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Elevated Polyreactive Immunoglobulin G in Immune-Mediated Liver Injuries With the Need for Immunosuppressive Therapy. [PDF]

Liver Int
Kirchner T, Dalekos GN, Zachou K, Robles-Díaz M, Andrade RJ, Sebode M, Lohse A, Janik MK, Milkiewicz P, Kolev M, Semmo N, Bruns T, Gevers TJ, Beretta-Piccoli BT, Wedemeyer H, Jaeckel E, Taubert R, Engel B, pIgG study group.   +18 more
europepmc   +1 more source

Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Although the American Diabetes Association (ADA) recently established a diagnostic algorithm for the early detection of liver fibrosis among high‐risk individuals, its implications for chronic kidney disease (CKD) risk stratification remain unclear.
Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim   +4 more
wiley   +1 more source

From Immunization to Autoimmunity: A Deep Dive Into Post-COVID-19 Vaccine Reactions-A Narrative Review. [PDF]

Health Sci Rep
Yousefi-Hashemabad MJ, Hashemi S, Saleki K, Nourbakhsh SMK, Saleki A, Hassanzadeh Z, Azadmehr A.   +6 more
europepmc   +1 more source

Real‐world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron‐overloaded patients

British Journal of Haematology, EarlyView.
Barbara Gianesin, Antonietta Zappu, Giovanni Battista Ferrero, Carmen Maria Gaglioti, Michele Santodirocco, Giuseppe Fania, Giovanna Graziadei, Daniele Lello Panzieri, Antonella Massa, Tommaso Mina, Francesca Polese, Angelantonio Vitucci, Francesco Arcioni, Maria Caterina Putti, Valerio Cecinati, Ilaria Fotzi, Paola Maria Grazia Sanna, Antonio Cappello, Filomena Longo, Roberto Lisi, Annamaria Pasanisi, Daniela Pietrasanta, Monica Bocchia, Elisa Bertoni, Antonella Cossu, Marilena Serra, Susanna Barella, Antonia Gigante, Gian Luca Forni, Raffaella Origa   +29 more
wiley   +1 more source

Serum IGF‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho, Hye‐Sun Park, Tae Seop Lim, Jong Ho Jhee, Jong Hyun Jhee   +4 more
wiley   +1 more source

Geographic distribution and demographic patterns of primary biliary cholangitis and autoimmune hepatitis in Colombia: a national population-based administrative study (2018-2024). [PDF]

Ann Gastroenterol
García-Marmolejo JP, Hernández-Meza JS, Corredor-Gaitán MX, Ávila-Almanza F, Suárez-Quintero CY.   +4 more
europepmc   +1 more source